HANK & LIN'S GROUP

The past is prologue and the future is scintillating

68Ga-P16-093

[68Ga]Ga-PSMA-093 (68Ga-P16-093):

  • Structure: [68Ga]Ga-PSMA-093 is a second-generation PSMA ligand that is an analog of PSMA-11. It was designed to potentially improve upon the limitations of PSMA-11, such as better tumor uptake, improved pharmacokinetics, and enhanced sensitivity for imaging small metastases or early-stage prostate cancer.
  • Target: Like PSMA-11, it targets PSMA (Prostate-Specific Membrane Antigen), but PSMA-093 may have a higher affinity or different binding properties, making it potentially more effective for certain applications.
  • Pharmacokinetics: It might have improved tumor-to-background ratios or clearance rates, resulting in more precise imaging and fewer false positives or negatives, especially in low-exposure areas like lymph nodes or small distant metastases.
  • Clinical Application: This agent could be used similarly to PSMA-11 but with potentially enhanced imaging sensitivity. Its clinical utility would depend on trials showing advantages over PSMA-11 in terms of detection rates, especially in challenging prostate cancer cases or where early-stage cancer is hard to detect.
Hong, H., Wang, G., Ploessl, K., Zha, Z., Zang, J., Zhu, Z., Zhu, L. and Kung, H.F., 2022. Kit-based preparation of [68Ga] Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators. Nuclear Medicine and Biology, 106, pp.1-9.

Publishcation：

  1. Wang, Guochang, Linlin Li, Jie Zang, Haiyan Hong, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-Head Comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer: A Pilot Study."Clinical Nuclear Medicine(2023);48: 289–295.  DOI:10.1097/RLU.0000000000004566
  2. Bahler, Clinton D., Mark A. Green, Mark A. Tann, Jordan K. Swensson, Katrina Collins, David Alexoff, Hank Kung et al. "Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care." InUrologic Oncology: Seminars and Original Investigations, vol. 41, no. 1, pp. 48-e1. Elsevier, 2023.

    https://doi.org/10.1016/j.urolonc.2022.10.003

  3. Wang, Guochang, Linlin Li, Jiarou Wang, Jie Zang, Jingci Chen, Yu Xiao, Xinrong Fan, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-head comparison of [68Ga] Ga-P16-093 and 2-[18F] FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study."European Journal of Nuclear Medicine and Molecular Imaging 50(2023):1499–1509.

    https://doi.org/10.1007/s00259-022-06101-3

  4. Wang, Guochang, Linlin Li, Ming Zhu, Jiarou Wang, Rongxi Wang, Weigang Yan, Lin Zhu, Hank F Kung, Zhaohui Zhu. "A prospective head‑to‑head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer". European Journal of Nuclear Medicine and Molecular Imaging 50, 3126–3136 (2023)

    https://doi.org/10.1007/s00259-023-06283-4

  5. Lee, Hwan, Joshua S. Scheuermann, Anthony J. Young, Robert K. Doot, Margaret E. Daube-Witherspoon, Erin K. Schubert, Matthew A. Fillare et al. "Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer." Molecular Imaging and Biology (2022): 1-11. https://doi.org/10.1007/s11307-022-01720-6

  6. Wang, Guochang, Haiyan Hong, Jie Zang, Qingxing Liu, Yuanyuan Jiang, Xinrong Fan, Zhaohui Zhu, Lin Zhu, and Hank F. Kung. "Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients." European journal of nuclear medicine and molecular imaging 49, no. 3 (2022): 1052-1062. https://doi.org/10.1007/s00259-021-05539-1
  7. Green, Mark A., Gary D. Hutchins, Clinton D. Bahler, Mark Tann, Carla J. Mathias, Wendy Territo, Justin Sims et al. "[68Ga] Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [68Ga] Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence." Molecular imaging and biology 22, no. 3 (2020): 752-763. https://doi.org/10.1007/s11307-019-01421-7
  8. Hong, Haiyan, Guochang Wang, Karl Ploessl, Zhihao Zha, Jie Zang, Zhaohui Zhu, Lin Zhu, and Hank F. Kung. "Kit-based preparation of [68Ga] Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators." Nuclear Medicine and Biology 106 (2022): 1-9. https://doi.org/10.1016/j.nucmedbio.2021.12.001
  9. Zha, Z., et al. "Synthesis and evaluation of a novel urea-based, 68Ga-complex for imaging PSMA binding in tumor". Nuclear Medicine and Biology, 2018, 59, 36–47.


Meeting Abstracts：

  1. Wang J, Li L, Wang R, Zhou Z, Zhu L, Yan W, Kung H, Zhu Z. [68Ga]Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer-Histopathologic Correlation. Journal of Nuclear MedicineJune 2024,65(supplement 2)241986
  2. Territo W, Hutchins G, Clint B, Tann M, Collins K, Mathias C, Alexoff D, Kung H, Green M. Selection of Optimal Quantification Metric in Static Prostate Cancer Imaging with the PSMA-targeted [68Ga]Ga-PSMA-11 and [68Ga]Ga-P16-093 PET Radiopharmaceuticals. Journal of Nuclear MedicineJune 2024,65(supplement 2)242185;
  3. Bahler, Clinton, Mark Green, Mark Tann, Katrina Collins, Jordan Swensson, Eric Brocken, Liang Cheng et al. "PD27-01 PREDICTING EXTRA-PROSTATIC EXTENSION (EPE) FOR SURGICAL GUIDANCE IN PROSTATE CANCER: A COMPARISON OF BIOPSY PATHOLOGY, MULTIPARAMETRIC MRI, AND PSMA-PET." The Journal of Urology 207, no. Supplement 5 (2022): e493.
  4. Green, Mark, Clint Bahler, Mark Tann, Gary Hutchins, Carla Mathias, Wendy Territo, Rumeal Whaley et al. "PSMA-targeted PET with [68Ga]Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy." Journal of Nuclear Medicine May 2020, 61 (supplement 1) 192.
  5. Whaley, Liang Cheng, David Alexoff, and Hank Kung. "PSMA-targeted PET with [68Ga]Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer." Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1252.
Wang, Guochang, et al.